Ceribell vs Neuropace
Ceribell and Neuropace are similar in size: $89.1m and $100.0m of revenue in their latest fiscal years. Ceribell grew faster (36.1% against 25.1%). Neuropace kept more of each dollar of sales as profit: a net margin of -21.5% against -60.0%. Ceribell carries less debt relative to equity (12.8% against 309.4%).
| Latest fiscal year | CeribellCBLL, 2025 | NeuropaceNPCE, 2025 |
|---|---|---|
| Revenue | $89.1m | $100.0m |
| Revenue growth | 36.1% | 25.1% |
| Net income | −$53.4m | −$21.5m |
| Operating margin | -65.6% | -16.3% |
| Net margin | -60.0% | -21.5% |
| Return on equity | -30.8% | -158.7% |
| Free cash flow | −$41.6m | −$11.3m |
| Cash | $40.5m | $21.7m |
| Total debt | $19.8m | $58.9m |
| Debt to equity | 12.8% | 309.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $49.5m |
| Employees | 327 | 209 |
| Market value | $1.09bn | $424m |
| Price vs our value range | — | — |
| Moat score | — | 37 (Weak) |
| Insider trades, 12 months | 0 buys, 100 sales | 0 buys, 1 sales |